This technology includes a fully automated computer aided diagnosis system to quantify myocardial blood flow (MBF) and myocardial perfusion reserve (MPR) pixel maps from the first-pass contrast-enhanced cardiac magnetic resonance (CMR) perfusion images. This system performs automated image registration, motion compensation, segmentation, and modeling to extract quantitative features from different myocardial regions of interest.
This technology includes a family of small-molecule antagonists that selectively block the 5-HT2B serotonin receptor—an upstream driver of tissue-remodeling—to address fibrotic, cardiopulmonary and related disorders. Built on a conformationally-locked “(N)-methanocarba” nucleoside scaffold, the compounds show nanomolar potency, >30–400-fold selectivity over the closely related 5-HT2C receptor, and favorable oral bioavailability in rodents.
Targeted toxins (e.g., immunotoxins) are therapeutics that have at least two important components: (1) a toxin domain that is capable of killing cells and (2) a targeting domain that is capable of selectively localizing the toxic domain to only those cells which should be killed. By selecting a targeting domain that binds only to certain diseased cells (e.g., a cell which only expresses a cell surface receptor when in a diseased state), targeted toxins can kill the diseased cells while allowing healthy, essential cells to survive.
This technology includes a fully automatic 3D image processing system to segment the heart as well as other organs from contrast-enhanced cardiac computed tomography (CCT) images. Our method detects four cardiac chambers including left ventricle, right ventricle, left atrium, right atrium, as well as the ascending aorta and left ventricular myocardium. It also classifies noncardiac tissue structures in the CCT images such as lung, chest wall, spine, descending aorta, and liver.
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway.
Description of Technology:
Value Proposition
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a hydrogel-based delivery system for the local administration of tofacitinib to improve transplant outcomes.
This technology includes a blood flow imaging method that allows for a higher density of smaller particles to be detected. Current imaging methods that are based on Doppler measurements are limited by the discontinuity in the capillary flow in the space between red blood cells. The core technology is to use a scattering agent to enhance capillary flow or microcirculation. This technology has been tested for optical coherence Doppler tomography, but can be expended to any Doppler based flow imaging techniques such as laser speckle imaging.
This technology includes the creation and use of A3 adenosine receptor (A3AR)-selective agonists for treating chemotherapy-induced peripheral neuropathy, chronic neuropathic pain, rheumatoid arthritis, psoriasis, and other conditions. A3 receptors for adenosine are found in most cells and endogenous activation of the A3 receptors can result in apoptosis, thereby relieving the inflammation or targeting a tumor. A3AR agonists have been a promising strategy for the treatment of various diseases.